证券日报网讯 2月11日，复星医药在互动平台回答投资者提问时表示，复宏汉霖是公司的控股子公司， 其收入全额纳入公司合并报表范围。创新药品收入方面，2025年公司前三季度创新药品收入超人民币67 亿元，较上年同期增长18.09%，并呈现稳健增长态势。随着2025年复迈宁、复妥宁、万缇乐、普瑞尼 等产品新获纳入国家医保目录以及奕凯达新获纳入商保创新药品目录，公司创新药品有望进一步扩大市 场覆盖、为收入提供增量。此外，公司创新管线临床开发的持续推进，也有望为后续年度公司创新药品 收入的增长提供新的动力。 （文章来源：证券日报） ...

Core Insights - The company reflects on a year of significant achievements in the biopharmaceutical sector, highlighting the successful clinical use of its innovative drug, Revamin, and the approval of multiple CAR-T products, showcasing its commitment to addressing rare diseases and cancer treatment gaps [3][6][33] - Club Med has seen substantial growth, with global revenue projected to increase from €1.5 billion in 2015 to €2.1 billion in 2024, and operating profit has grown over five times, indicating strong market demand for innovative travel experiences [9][40] - The company emphasizes its focus on user-centered product development in the tourism sector, aiming to enhance family vacation experiences rather than merely creating tourist attractions [6][38] Biopharmaceutical Innovations - Revamin has been officially launched for clinical use, filling a treatment void for rare tumors in China [3][7] - The company has successfully developed and received approval for multiple innovative drugs, including the first CAR-T product for gastric cancer, which has been recognized as a breakthrough therapy [6][38] - Since 2019, the company has launched a total of 12 innovative drugs, demonstrating its ongoing commitment to patient care and treatment advancements [3][33] Tourism and Leisure Sector - Club Med's performance has reached new heights, with an increasing number of families prioritizing snow vacations, supported by the ongoing development of the "Super Mediterranean" project [6][38] - The company has introduced three core product lines in the tourism sector, focusing on user needs to enhance vacation experiences [6][38] - Atlantis in Sanya has solidified its leading position in the vacation market, with annual visitor numbers reaching 1.5 million [11][43] Globalization and Market Expansion - The company has achieved over 50% of its revenue from international markets, highlighting its successful globalization strategy [16][45] - The Portuguese insurance subsidiary has seen nearly 30% of its business come from international operations, contributing to a diversified revenue stream [16][45] - The company has established strategic partnerships, such as with Fakeeh Care Group in Saudi Arabia, to expand its CAR-T technology internationally [16][46] Cultural and Community Engagement - The company has actively engaged in cultural initiatives, such as the successful summer event at Yuyuan Garden, attracting over 7.5 million visitors, with a significant portion being young people [52] - The company has been recognized for its commitment to social responsibility, being included in the S&P Global Sustainability Yearbook for the second consecutive year [54] - Ongoing support for educational and healthcare initiatives, including donations to Fudan University Affiliated Hospital, reflects the company's dedication to community welfare [57]

Core Viewpoint - Fosun Pharma's stock price increased by approximately 4% during trading, reflecting positive market sentiment following the release of its financial results for the nine months ending September 30, 2025, which showed a mixed performance in revenue and profit [1] Financial Performance - The company reported a revenue of 29.393 billion yuan, a decrease of 4.91% year-on-year [1] - Net profit attributable to shareholders was 2.523 billion yuan, an increase of 25.5% year-on-year [1] - Basic earnings per share stood at 0.95 yuan [1] Key Drivers of Performance - The increase in net profit was primarily attributed to gains from the sale of remaining equity in United Family Healthcare and other non-core assets [1] - The company is actively advancing the launch of innovative products, with several new drug approvals in September, including a new indication for the small molecule CDK4/6 inhibitor and approvals for other products in the U.S. and EU [1] Future Outlook - Analysts believe that the ongoing launch of innovative drugs will contribute to a recovery in revenue for the company [1]

Core Viewpoint - Fosun Pharma's stock has seen an increase of nearly 4%, with a current price of HKD 23.16, following the release of its financial results for the nine months ending September 30, 2025, which showed a mixed performance in revenue and profit [1] Financial Performance - The company reported a revenue of CNY 29.393 billion, a decrease of 4.91% year-on-year [1] - Net profit attributable to shareholders was CNY 2.523 billion, reflecting a year-on-year increase of 25.5% [1] - Basic earnings per share stood at CNY 0.95 [1] Key Drivers of Performance - The increase in net profit is primarily attributed to gains from the sale of remaining equity in United Family Healthcare and other non-core assets [1] - The company has been actively pursuing the launch of innovative products, with recent approvals for new indications and products in both domestic and international markets [1] Product Development and Market Expansion - In Q3 2025, Fosun Pharma continued to advance its innovative drug launches, including the approval of a new indication for the small molecule CDK4/6 inhibitor, Ruzhoning, in September [1] - The HLX14 injection has received approval for sale in the US and EU, while the FKC889 injection has been submitted for domestic approval and accepted by the National Medical Products Administration [1] - Analysts believe that the ongoing launch of innovative drug products will drive revenue recovery for the company [1]

Company Performance - The company is expected to achieve net profits of 3.32 billion, 3.96 billion, and 4.77 billion from 2025 to 2027, with year-over-year growth rates of +19.9%, +19.4%, and +20.4% respectively, and corresponding EPS of 1.2, 1.5, and 1.8 [1] - For the first three quarters of 2025, the company reported revenue of 29.39 billion and a net profit attributable to shareholders of 2.52 billion, representing a year-over-year increase of +25.5% [1] - In Q3 alone, the company achieved revenue of 9.88 billion and a net profit of 0.82 billion, with year-over-year growth of +4.5% [1] Revenue Impact - Overall revenue has experienced slight negative growth due to the impact of centralized drug procurement, particularly affecting generic drugs, while innovative drugs have shown robust growth [2] - In the first three quarters, revenue from innovative drugs exceeded 6.7 billion, marking an 18.1% year-over-year increase [2] - The company continues to advance the launch of innovative products, with new approvals for several drugs in September, which are expected to drive revenue recovery [2] Cost and Margin Analysis - The gross margin for Q3 increased slightly to 48.4%, benefiting from a higher proportion of high-margin innovative drug products [3] - The expense ratio for Q3 was 44.1%, an increase of 1.4 percentage points year-over-year, with a notable rise in R&D expenses by 2.2 billion due to increased investment in innovative platforms [3] - Sales expense ratio decreased by 1.4 percentage points, while management expenses increased by 0.2 percentage points, and financial expenses decreased by 0.8 percentage points [3]

Company Performance - The company is expected to achieve net profits of 3.32 billion, 3.96 billion, and 4.77 billion CNY from 2025 to 2027, with year-over-year growth rates of +19.9%, +19.4%, and +20.4% respectively, and corresponding EPS of 1.2, 1.5, and 1.8 CNY, leading to H-share PE ratios of 17X, 14X, and 12X [1] - For the first three quarters of 2025, the company reported revenue of 29.39 billion CNY and a net profit attributable to shareholders of 2.52 billion CNY, reflecting a year-over-year increase of +25.5% [2] - In Q3 alone, the company achieved revenue of 9.88 billion CNY and a net profit of 820 million CNY, with year-over-year growth of +4.5% [2] Revenue Impact and Innovation - Overall revenue has been slightly negatively impacted by centralized procurement policies affecting generic drugs, while innovative products continue to grow rapidly, with innovative drug revenue exceeding 6.7 billion CNY in the first three quarters, marking an 18.1% year-over-year increase [3] - The company has made significant progress in launching innovative products, with new approvals for drugs such as the small molecule CDK4/6 inhibitor and others in both domestic and international markets, which are expected to drive revenue recovery [3] Cost Structure and R&D Investment - The gross margin for Q3 was 48.4%, a slight increase of 0.3 percentage points, primarily due to a higher proportion of high-margin innovative drug products [4] - R&D expenses increased significantly by 2.2 billion CNY year-over-year, driven by investments in innovative platforms and high-value pipelines, indicating a strong commitment to R&D despite short-term profit impacts [4]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to less than 35% [2][6]. Core Insights - The company reported a revenue of 29.39 billion RMB for the first three quarters of 2025, reflecting a year-over-year decline of 4.9%. However, the net profit attributable to the parent company was 2.52 billion RMB, showing a year-over-year increase of 25.5% [6]. - The company has faced challenges due to centralized drug procurement affecting revenue from generic drugs, but innovative products have continued to grow, with innovative drug revenue exceeding 6.7 billion RMB, a year-over-year increase of 18.1% [6]. - The gross margin for Q3 was 48.4%, a slight increase of 0.3 percentage points year-over-year, driven by a higher proportion of high-margin innovative drug products [6]. - The report anticipates net profits for 2025-2027 to be 3.32 billion RMB, 3.96 billion RMB, and 4.77 billion RMB, respectively, with year-over-year growth rates of 19.9%, 19.4%, and 20.4% [6][7]. Financial Summary - The company’s projected net profit for 2025 is 3.32 billion RMB, with an EPS of 1.24 RMB, and a corresponding H-share P/E ratio of 17.21 [7]. - Revenue is expected to reach 44.87 billion RMB in 2025, with a slight increase in operating profit to 5.04 billion RMB [9]. - The company’s cash flow from operating activities is projected to be 4.32 billion RMB in 2025, indicating a positive cash flow trend [10].

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for a new indication of the drug FCN-437c (commercial name: Fuzhuoning) for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1] Group 1: Drug Approval Details - The newly approved indication is for use in combination with aromatase inhibitors as initial endocrine therapy [1] - FCN-437c is an innovative small molecule CDK4/6 inhibitor with independent intellectual property rights owned by the group [1] - The drug is characterized as an oral, potent, highly selective, and structurally novel small molecule [1] Group 2: Development Background - FCN-437c was included in the national "Major New Drug Creation" science and technology major project in 2018 [1]

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of a new drug, Citrate Vofopitant Capsules, for specific breast cancer treatment [1] - The approved indication is for the use of the drug in combination with Fulvestrant for adult patients with hormone receptor-positive and HER2-negative recurrent or metastatic breast cancer who have previously undergone endocrine therapy [1] - The new drug is a novel small molecule CDK4/6 inhibitor, and the total R&D investment for this drug is approximately RMB 601 million, expected to be completed by April 2025 [1]